CenterBook Partners LP Has $3.33 Million Stock Position in Neogen Corporation $NEOG
CenterBook Partners LP significantly reduced its stake in Neogen Corporation (NASDAQ:NEOG) by 55.4% in Q3, now holding 583,007 shares valued at $3.33 million. Despite this, institutional investors collectively own 96.73% of NEOG, with major increases from Vanguard Group Inc. and new stakes from firms like ING Groep NV. Analyst sentiment for Neogen is mixed, with an average "Hold" rating and a target price of $10.67, even as the company recently exceeded earnings estimates.
Neogen stock hits 52-week high at 11.16 USD
Neogen Corporation's stock has reached a new 52-week high of $11.16, reflecting robust market performance with a 98.38% return over six months and attracting investor confidence. Despite not being profitable in the last twelve months, the company is expected to become profitable this year and recently surpassed earnings and revenue expectations in its Q2 FY2026 report. Analysts have raised price targets, highlighting the strong performance of its Food Safety segment as a key growth driver.
Nassif Mikheal, CEO of Neogen, buys $251 in Neog stock
Neogen CEO Nassif Mikheal recently purchased 23 shares of common stock for $251, with the shares now indirectly owned by his son. This director transaction follows Neogen's strong Q2 2026 financial results, which surpassed earnings and revenue expectations, leading to reiterated positive ratings from analysts and an increased price target from Guggenheim.
Nassif Mikheal, CEO of Neogen, buys $251 in Neog stock
Neogen CEO Nassif Mikheal purchased 23 shares of NEOG stock for $251 on February 17, 2026, increasing his indirect holdings to 704 shares through his son's ownership. This transaction follows Neogen's strong Q2 fiscal year 2026 results, which surpassed earnings expectations and led to raised company guidance and positive analyst reactions from William Blair and Guggenheim.
Neogen Corporation (NASDAQ:NEOG) Short Interest Down 15.8% in January
Neogen Corporation (NASDAQ:NEOG) experienced a 15.8% decrease in short interest in January, totaling 11,865,302 shares, representing approximately 5.5% of its shares sold short. Major institutional investors, particularly Goldman Sachs, increased their stakes, while the company reported better-than-expected Q1 earnings but a significant negative net margin. Analysts currently hold a "Hold" consensus rating with an average target price of $10.67.
Neogen (NASDAQ:NEOG) Upgraded at Wall Street Zen
Wall Street Zen upgraded Neogen (NASDAQ:NEOG) from a "hold" to a "buy" rating on Saturday, February 14, 2026. While the company recently beat earnings estimates with EPS of $0.10 and revenue of $224.7M, it remains unprofitable. The stock currently trades around $10.94, with an average analyst consensus rating of "Hold" and a price target of $10.67.
ING Groep NV Makes New Investment in Neogen Corporation $NEOG
ING Groep NV has significantly invested in Neogen Corporation (NASDAQ:NEOG), acquiring over 14 million shares valued at approximately $80.29 million during the third quarter, representing 6.47% ownership. Other institutional investors have also increased their holdings. Analyst ratings for Neogen are mixed, with an average "Hold" rating and a price target of $10.67, while the company recently reported earnings that beat analyst estimates.
Does Neogen’s Vet HYCOAT Recall Reveal Deeper Quality-Control Risks For Its Growth Story (NEOG)?
Neogen Corporation (NEOG) issued a voluntary recall of its Vet HYCOAT Hyaluronate Sodium Sterile Solution due to microbial contamination and reported adverse events when used off-label. This recall highlights potential quality-control issues with third-party manufacturers, adding a layer of risk to Neogen's investment narrative, especially considering its recent stock price increase and the company's unprofitability. While currently viewed as a contained setback, it emphasizes the need for management to demonstrate its quality systems can support its growth ambitions.
Neogen Recall Puts Veterinary Quality Controls And Investor Confidence In Focus
Neogen Corporation initiated a voluntary recall of its HYCOAT Hyaluronate Sodium Sterile Solution due to microbial contamination, affecting its standing in the veterinary market. This recall places scrutiny on Neogen's quality controls, supplier oversight, and its Animal Safety segment's profitability struggles. Investors are watching how the company navigates regulatory relationships, restores trust, and manages financial impacts in a competitive landscape with rivals like Zoetis and IDEXX.
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Neogen Corporation's stock has seen a 46% jump in the last month, but its price-to-sales (P/S) ratio of 2.5x still appears low compared to the Medical Equipment industry average. This low P/S ratio is attributed to the company's declining revenue over the past year and a forecast of continued revenue decrease by analysts, contrasting sharply with the industry's expected growth. The article suggests that until Neogen improves its top-line growth, a higher P/S ratio and significant stock price appreciation are unlikely.
Is Neogen (NEOG) Mispriced After Its Recent 51% Year To Date Rally
Neogen (NEOG) has seen a significant rally of 51% year-to-date, prompting an analysis of its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is 61.0% undervalued with an intrinsic value of $27.18, compared to its current price of $10.59. However, its Price-to-Sales (P/S) ratio of 2.62x is above Simply Wall St's proprietary Fair Ratio of 1.13x, indicating it might be overvalued by this metric.
Neogen Corporation stock hits 52-week high at $10.90
Neogen Corporation (NEOG) stock has reached a 52-week high of $10.90, reflecting a 4.53% increase over the past year and demonstrating positive investor confidence and growth potential. This milestone follows strong Q2 2026 financial results, where the company surpassed earnings and revenue expectations, driven primarily by its Food Safety segment. Analyst firms William Blair and Guggenheim have responded positively, with Guggenheim raising its price target to $12.00 while maintaining a Buy rating.
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Neogen Corporation's stock has surged 46% in the last month, yet its price-to-sales (P/S) ratio remains modest compared to the Medical Equipment industry, primarily due to recent revenue declines and a forecast of continued negative growth. While the company saw a 40% revenue rise over the last three years, the most recent year showed a 3.7% decrease, and analysts predict a 0.4% annual decline for the next three years, contrasting sharply with the industry's expected 127% growth. This weak revenue outlook contributes to investor sentiment preventing a higher P/S ratio and suggests that significant stock price increases are unlikely without improved top-line performance.
Neogen Corporation (NEOG): A Bull Case Theory
This article summarizes a bullish thesis on Neogen Corporation (NEOG), highlighting that the company's 2Q 2026 results showed an inflection point and marked a stabilization of its self-inflicted downturn. The turnaround is attributed to new CEO Mike Nassif's operational focus, leading to improved core organic revenue growth, adjusted EBITDA expansion, and an upward revision to full-year guidance. While the stock has recovered, the thesis suggests further upside due to ongoing operational improvements, recovery in the Genomics business, and declining capital intensity.
Short Interest in Neogen Corporation (NASDAQ:NEOG) Decreases By 17.6%
Neogen Corporation (NASDAQ:NEOG) experienced a significant 17.6% decrease in short interest as of January 15th, totaling 14,099,129 shares. This reduction indicates decreased short-pressure on the stock, with 6.5% of the company's stock sold short and a short-interest ratio of 2.3 days. The company recently beat quarterly earnings expectations and has received a mixed "Hold" rating from Wall Street analysts with an average target price of $10.67.
Zacks Research Forecasts Neogen's Q3 Earnings (NASDAQ:NEOG)
Zacks Research has lowered its Q3 2026 EPS estimate for Neogen (NASDAQ:NEOG) to $0.04 and projects FY2026 EPS of $0.24, significantly below the market consensus of $0.38. This comes despite Neogen beating Q3 estimates with $0.10 EPS and $224.69 million in revenue, though the company reported a negative net margin of -68.47% and a 2.9% year-over-year revenue decrease. Analyst coverage remains mixed with an average "Hold" rating and a consensus price target of $10.67, with institutional investors holding approximately 96.73% of the stock.
Neogen Corporation (NASDAQ:NEOG) Given Average Recommendation of "Hold" by Brokerages
Six brokerages have issued a consensus "Hold" rating for Neogen Corporation (NASDAQ:NEOG), with an average one-year price target of $10.67. Institutional investors hold a significant 96.73% stake in the company, with notable recent investments from ING Groep NV and Norges Bank. Despite beating Q4 EPS and revenue estimates, Neogen experienced a 2.9% year-over-year revenue decline and a negative net margin of 68.47%.
Microbial contamination prompts Neogen recall of pet wound solution
Neogen Corporation has issued a voluntary nationwide recall of all lots within expiry of its Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution for dogs, cats, and horses. The recall stems from microbial contamination found in certain lots of the 10 mL/50 mg product vials, which has led to adverse event reports in horses when used intraarticularly, inconsistent with its labeled use. While no adverse events have been reported for labeled topical use, the company is also recalling 2 mL/20 mg vials out of caution and is working with the FDA.
Animal Health Firm Neogen Initiates Recall Of Vials Over Microbial Contamination
Neogen (NASDAQ: NEOG) has initiated a nationwide recall of all unexpired lots of its Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution due to microbial contamination. The product is used for topical wound management in dogs, cats, and horses, but contamination was found in certain batches, leading to adverse event reports in horses when used off-label. This recall includes both 10 mL/50 mg and 2 mL/20 mg vials, as the affected products are no longer considered sterile and pose an infection risk, particularly if injected.
Neogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution
Neogen Corporation is voluntarily recalling all lots of its Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination. The recall covers both 10 mL/50 mg and 2 mL/20 mg vials, primarily affecting products intended for dogs, cats, and horses. This action was taken after reports of adverse events in horses following off-label intraarticular injections, although no issues have been reported for its labeled use as a topical wound management system.
Mizuho Markets Americas LLC Takes $11.42 Million Position in Neogen Corporation $NEOG
Mizuho Markets Americas LLC acquired a new 2 million share stake in Neogen Corporation (NASDAQ:NEOG) valued at $11.42 million during the third quarter. This investment represents about 0.92% of Neogen. Despite beating analyst estimates for EPS and revenue, Neogen reported a negative net margin of 68.47% and a 2.9% year-over-year revenue decline. The stock currently holds an average "Hold" rating from analysts with an average price target of $10.67.
Neogen (NEOG) Q2 2026 Earnings Call Transcript
Neogen (NEOG) reported a return to positive core growth in both Food Safety and Animal Safety segments for Q2 2026, with improved gross and adjusted EBITDA margins driven by increased volume and cost reductions. The company raised its full-year guidance, anticipating revenue between $845 million and $855 million and adjusted EBITDA of approximately $175 million. Strategic initiatives like the Petrifilm integration and the divestiture of non-core businesses are progressing, aiming to reduce debt and enhance focus on core operations.
Neogen CEO Nassif Mikheal buys $1278 in shares
Neogen CEO Nassif Mikheal purchased 137 shares of the company's common stock for $1278, which are indirectly owned by his son. This buy follows a significant 92.28% surge in the food safety company's stock over the past six months. Despite being marginally overvalued compared to its fair value, analysts expect the company to return to profitability this year, especially after surpassing Q2 fiscal year 2026 earnings and revenue expectations.
Neogen (NEOG) Is Up 26.5% After Raising 2026 Outlook And Trimming Losses - Has The Bull Case Changed?
Neogen (NEOG) has seen a significant stock increase after raising its full-year 2026 revenue outlook to $845 million–$855 million and reducing its quarterly net loss. The company is implementing cost-saving initiatives and portfolio divestitures to improve profitability and reshape its focus on Food and Animal Safety. While the raised outlook and cost savings support an improved earnings profile, the fair value estimates from the Simply Wall St community suggest a potential downside compared to the current price, indicating that execution on these strategies is crucial.
Neogen announces 2 senior leadership appointments
Neogen Corporation has announced two key senior leadership appointments. Joe Freels has been named senior vice president and chief commercial officer, and Tammi Ranalli, Ph.D., will serve as senior vice president and general manager of Global Food Safety. These appointments aim to strengthen Neogen's Food Safety business through their combined commercial, scientific, and operational expertise.
Guggenheim Raises Price Target for Neogen (NEOG) to $12 | NEOG S
Guggenheim has increased its price target for Neogen (NEOG) from $8 to $12, while maintaining a 'Buy' rating, representing a 50% increase. This adjustment follows a series of analyst rating changes for Neogen, including upgrades and downgrades by other firms. Despite the positive outlook from Guggenheim, the average target price from four analysts is $8.63, implying a potential downside, whereas GuruFocus estimates a GF Value of $13.64, suggesting an upside.
Neogen Corp (NASDAQ:NEOG) Revenues Decline
Neogen Corp (NASDAQ:NEOG) reported second-quarter earnings that surpassed analyst expectations despite a slight year-over-year revenue decline. The company's Food Safety segment saw a modest increase, while Animal Safety revenue dropped due to divestitures. Neogen raised its full-year fiscal 2026 outlook and expects $20 million in annualized savings from cost structure improvements.
Neogen stock steadies near $10 after 32% surge on raised outlook; next catalyst is Jan. 14
Neogen (NEOG) stock remained steady near $9.74 in premarket trading after a 31.6% surge following a raised fiscal 2026 revenue outlook to $845 million–$855 million, exceeding Wall Street estimates. The company reported a net loss of $15.9 million but adjusted profit of 10 cents per share and anticipates adjusted EBITDA around $175 million. Investors are now looking for updates on Petrifilm integration and manufacturing, with the next significant event being CEO Mike Nassif's presentation at the J.P. Morgan Healthcare Conference on January 14.
NEOG Q4 Deep Dive: Operational Improvements and New Leadership Drive Upbeat Outlook
Neogen (NASDAQ:NEOG) reported strong Q4 CY2025 results, exceeding revenue and EPS expectations, driven by operational improvements, new leadership hires, and a focus on cost structure and commercial execution. The company raised its full-year revenue and EBITDA guidance, reflecting confidence in its transformation strategy and continued emphasis on efficiency. Management highlighted a renewed focus on specific product lines, cost savings initiatives, and a more process-oriented commercial approach despite lingering macroeconomic challenges.
Neogen's Raised Outlook Fuels Turnaround Hopes, Stock Soars
Neogen (NASDAQ: NEOG) reported better-than-expected Q2 2026 financial results, with adjusted earnings of 10 cents per share against a 6 cent consensus, and sales of $224.69 million, exceeding the $207.85 million consensus. The company raised its fiscal 2026 sales guidance to $845 million-$855 million and expects adjusted EBITDA around $175 million, which led to a significant jump in its stock price. While a William Blair analyst maintained a Market Perform rating due to the early stage of the turnaround, they acknowledged the improving narrative under new leadership.
Neogen stock climbs on Q2 beat, guidance hike (NEOG:NASDAQ)
Shares of Neogen Corporation (NEOG) surged nearly 28% after the company reported better-than-expected Q2 FY26 financials. The food and animal safety company also raised its full-year financial outlook, despite a ~3% YoY decrease in Q2 revenue, which still surpassed analyst estimates.
Neogen Corporation (NASDAQ:NEOG) Q2 2026 Earnings Call Transcript
Neogen Corporation reported strong Q2 2026 earnings, exceeding expectations with a reported EPS of $0.10 against an anticipated $0.07. The company's CEO, Mike Nassif, and new CFO, Brian Rigsby, highlighted a return to positive core growth across the enterprise and improved adjusted EBITDA margins, leading to a raised full-year guidance for fiscal 2026. The call also emphasized ongoing transformation efforts, including cost structure improvements, commercial excellence initiatives, and the successful progress of the Petrifilm integration and the planned divestiture of its genomics business.
Neogen (NEOG) Hits 10-Month High on Earnings, Upbeat Outlook
Neogen (NEOG) reached a 10-month high after reporting strong second-quarter earnings for fiscal year 2026, narrowing its net loss significantly and swinging to a net income for the six-month period. Despite a slight dip in Q2 revenues, the company raised its full-year 2026 revenue outlook and projected higher adjusted EBITDA, leading to investor optimism. The CEO highlighted the initial phase of strategic transformation and improvements in core revenue growth and profitability despite macro headwinds.
Neogen (NEOG) Hits 10-Month High on Earnings, Upbeat Outlook
Neogen (NEOG) shares jumped to a 10-month high after the company reported strong second-quarter fiscal year 2026 earnings, narrowing its net loss significantly. Despite a slight dip in Q2 revenues, Neogen raised its full-year 2026 revenue guidance to $845 million-$855 million and projected higher adjusted EBITDA, signaling an optimistic outlook for its "strategic transformation."
Food safety company raises full-year forecast after quarterly loss
Neogen (NEOG) reported a net loss of $15.9 million in the second quarter of fiscal year 2026 but raised its full-year revenue and Adjusted EBITDA guidance. The company experienced a 2.8% year-over-year revenue decrease but a 2.9% core revenue increase, attributing the improved outlook to strategic transformation initiatives and strengthening its leadership team. This positive forecast comes despite macro headwinds, with a focus on integrating Petrifilm manufacturing and improving profitability.
Why Neogen Stock Blasted More Than 31% Higher Today
Neogen's stock surged over 31% after reporting its fiscal second-quarter 2026 earnings. Despite year-over-year declines in revenue and net income, both metrics surpassed analyst expectations, and the company raised its full-year guidance. However, the author expresses skepticism about the stock's future given the top-line decline.
Neogen (NASDAQ:NEOG) Shares Gap Up After Earnings Beat
Neogen (NASDAQ:NEOG) shares gapped up by approximately 28% after reporting stronger-than-expected Q2 earnings and revenue, and raising its full-year 2026 revenue guidance. Despite these positive indicators, the company recorded operating and net losses, and a decline in year-over-year revenue, leading to mixed analyst sentiment and profitability concerns. Institutional ownership remains high at 96.73%.
Neogen Corporation Q2 2026 Financial Results
Neogen Corporation reported its financial results for Q2 fiscal year 2026, showing mixed performance with a 2.8% decrease in revenues to $224.7 million but a significant reduction in net loss. The Food Safety segment grew by 0.8%, while Animal Safety declined by 11.8%. The company raised its full-year revenue guidance to $845 million-$855 million and Adjusted EBITDA to approximately $175 million.
Dự báo nâng cấp của Neogen thắp lên hy vọng phục hồi, cổ phiếu tăng vọt
Neogen Corp. (NASDAQ: NEOG) đã báo cáo kết quả quý 2 năm tài chính 2026 vượt xa kỳ vọng của các nhà phân tích, với lợi nhuận điều chỉnh 0,10 USD/cổ phiếu và doanh thu 224,69 triệu USD. Công ty đã nâng dự báo doanh thu cả năm lên 845-855 triệu USD, dẫn đến việc cổ phiếu tăng vọt 29,34%. Mặc dù William Blair giữ đánh giá "Market Perform" do quá trình phục hồi còn sớm, Neogen vẫn ghi nhận động lực tích cực dưới sự lãnh đạo mới.
Neogen: Tổng quan về kết quả tài chính quý hai
Neogen Corp. reported a net loss of $15.9 million, or $0.07 per share, for its second financial quarter. However, adjusted earnings per share reached $0.10, surpassing analyst expectations of $0.07. The medical diagnostics kit manufacturer also exceeded revenue forecasts, generating $224.7 million compared to analyst predictions of $209.7 million, and anticipates full-year revenue between $845 million and $855 million.
Neogen (NASDAQ:NEOG) Beats Expectations in Strong Q4 CY2025, Stock Jumps 19.8%
Neogen (NASDAQ:NEOG) reported strong Q4 CY2025 results, significantly beating Wall Street's revenue and adjusted EPS expectations. Despite a year-on-year revenue decline of 2.8%, the company raised its full-year revenue and EBITDA guidance, leading to a 19.8% jump in its stock price. This quarter marked a positive "beat and raise" performance, though long-term growth and profitability trends remain key considerations for investors.
Neogen: Fiscal Second Quarter Earnings Overview
Neogen Corp. reported a net loss of $15.9 million for its fiscal second quarter, or $0.07 per share. However, adjusted earnings per share reached $0.10, surpassing analyst expectations of $0.07. The company's revenue of $224.7 million also exceeded forecasts, and Neogen projects full fiscal year revenue between $845 million and $855 million.
Neogen: Fiscal Q2 Earnings Snapshot
Neogen Corp. (NEOG) reported a fiscal second-quarter loss of $15.9 million, or 7 cents per share, which adjusted for one-time events, amounted to 10 cents per share. This exceeded Wall Street expectations of 7 cents per share. The company's revenue of $224.7 million also beat forecasts, and Neogen provided a full-year revenue outlook between $845 million and $855 million.
Neogen: Fiscal Q2 Earnings Snapshot
Neogen Corp. (NEOG) reported a fiscal second-quarter loss of $15.9 million, or 7 cents per share, which adjusted for one-time items, was 10 cents per share, surpassing Wall Street expectations. The medical testing kit maker also exceeded revenue forecasts with $224.7 million for the period and projects full-year revenue between $845 million and $855 million.
A Peek at Neogen's Future Earnings
Neogen (NASDAQ: NEOG) is scheduled to release its quarterly earnings report on Thursday, 2026-01-08, with analysts estimating an EPS of $0.06. The company has a "Neutral" consensus rating from analysts, with an average one-year price target of $8.25, indicating an 11.34% potential upside. Despite strong net margin and return on assets, Neogen has faced challenges with revenue growth and return on equity compared to its peers.
Neogen Corporation (NASDAQ:NEOG) Receives Average Rating of "Hold" from Analysts
Neogen Corporation (NASDAQ:NEOG) has received an average "Hold" rating from six brokerages, with an average one-year target price of $8.83. Institutional investors hold a significant 96.73% of the company's stock, with Millennium Management LLC recently opening a substantial stake. The company currently trades at $7.41, with a market capitalization of $1.61 billion and a negative trailing P/E ratio.
Neogen (NEOG) Q4 Earnings Report Preview: What To Look For
Neogen (NEOG) is set to report its Q4 earnings before the bell on Thursday. Analysts expect a 9.3% year-on-year revenue decline to $209.7 million and adjusted earnings of $0.07 per share. Despite past revenue misses, investor sentiment in the healthcare equipment and supplies segment is positive, with Neogen's stock up 27.5% over the last month.
Neogen appoints new chief commercial officer and food safety head
Neogen Corporation has appointed Joe Freels as Senior Vice President and Chief Commercial Officer, and Dr. Tammi Ranalli as Senior Vice President and General Manager of Global Food Safety. Freels will lead the global Food Safety commercial strategy, effective immediately, while Dr. Ranalli will manage the global Food Safety portfolio and strategy starting Wednesday. These appointments are part of Neogen's ongoing leadership and financial strategy adjustments, following a credit rating downgrade due to elevated leverage.
Should Neogen’s (NEOG) New Commercial Leaders Reshape Its Global Food Safety Investment Narrative?
Neogen Corporation has appointed Joe Freels and Dr. Tammi Ranalli to lead its global food safety commercial operations, signaling a strengthened focus on strategy and market execution. While these appointments are seen as incremental for the near term, they are critical for improving commercial execution and addressing ongoing profitability and integration challenges stemming from the 3M Food Safety acquisition. Investors should monitor how the new leadership drives improvement in key areas like Neogen's Listeria Right Now assay to bolster the company's food safety investment narrative.
Food safety company Neogen brings in two leaders to steer global strategy
Neogen Corporation announced two senior leadership appointments: Joe Freels as Senior Vice President and Chief Commercial Officer and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety. These strategic hires aim to strengthen Neogen's Food Safety business and drive global growth and innovation with their extensive commercial, scientific, and operational expertise.
